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AbstrACt
Introduction Diabetes and hypertension are two leading 
non-communicable conditions, which are suboptimally 
managed in India. Thus, innovative comprehensive 
approaches that can concomitantly improve their 
detection, prevention and control are warranted.
Methods and analysis UDAY, a 5-year initiative, aims 
to reduce the risk of diabetes and hypertension and 
improve management by implementing a comprehensive 
intervention programme in the two selected study sites, 
Sonipat and Visakhapatnam (Vizag). It has a pre-post 
evaluation design with representative cross-sectional 
surveys before and after intervention. Within these two 
sites, urban and rural subsites each with a total population 
of approximately 100 000 people each were selected and a 
baseline and postintervention assessment was conducted 
deploying five surveys [among general population 
(including body measurements or biosamples), patients, 
healthcare providers including physicians and pharmacists, 
health facilities], which will determine the knowledge 
levels about diabetes and hypertension, the proportion 
treated and controlled; the patient knowledge and self-
management skills; healthcare providers’ management 
practices; the level of access and barriers to obtaining 
care. The interventions will include: tailored health 
promotion for improving public knowledge; screening of 
adults aged ≥ 30 years for identifying those at high risk of 
diabetes and/or hypertension for linkage to the healthcare 
system; patient education using technology enabled 
community health workers, geographic information system 
(GIS) based mapping of the communities, healthcare 
provider training on management guidelines, community 
based diabetes registry and; advocacy to improve access 
to healthcare. The baseline surveys have been completed, 
the study areas mapped using GIS and the interventions 
are being implemented. UDAY is expected to increase over 
baseline the levels of: public knowledge about diabetes 
and hypertension; those treated and controlled; patient 
self-management skills; the use of guideline based 
management by providers and; access to healthcare, 
leading to improved health outcomes and inform 
development of a India relevant chronic care model. 
Ethics and dissemination Ethical clearance for conduct 
of the study was obtained from the Institutional Ethics 
Committee (IEC) of the Public Health Foundation of India. 
The findings will be targeted primarily at public health 
policymakers and advocates, but will be disseminated 
widely through other mechanisms including conference 
presentations and peer-reviewed publications, as well as 
to the participating communities.
IntroduCtIon
Non-communicable diseases (NCDs) are 
currently the leading cause of preventable 
death and disability in India, accounting for 
two out of every three deaths.1 Among NCDs, 
the prevalence of type 2 diabetes mellitus 
and hypertension has been rising rapidly. 
Currently there are about 69 million people 
with diabetes, a figure that is projected to 
further increase to a staggering 124 million 
by 2040.2 The number of individuals with 
hypertension is projected to increase to 
214 million by 2030 from 118 million in 
2000.3 4 Furthermore, diabetes and hyperten-
sion are important risk factors for both the 
major forms of cardiovascular disease (CVD 
(coronary heart disease and stroke)), highly 
strengths and limitations of this study
 ► Unique large community-based study in geograph-
ically and culturally diverse ‘real world’ settings in 
India for improving prevention and control of diabe-
tes and hypertension.
 ► Employs a comprehensive multilevel, multicom-
ponent intervention approach to target the general 
population, patients, providers and to strengthen the 
health system for improving prevention and control 
of diabetes and hypertension.
 ► Concomitantly addresses detection, prevention and 
management of both diabetes and hypertension.
 ► Extensively leverages mobile technology to enable 
health workers in task sharing as well as for elec-
tronic data capture.
 ► Quasi-experimental design with complex interven-
tion may hinder attribution of specific effect to indi-
vidual intervention components.
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prevalent and attributable to nearly half of all the deaths 
from NCDs.4 
Despite the availability of proven and effective treat-
ments, diabetes as well as hypertension detection and 
control rates are abysmally low in India with blood pres-
sure control among those with diabetes being even more 
suboptimal, with a huge gap between detection and 
adequate treatment.1 3 4 Thus, there is great potential 
and opportunity to reduce the rising burden of diabetes 
and hypertension as well as the associated vascular risk in 
India through concomitantly improving their detection, 
prevention and control.
To address this huge gap in the prevention and manage-
ment of both these conditions, we are undertaking 
a 5-year initiative entitled ‘UDAY’ (meaning dawn in 
Sanskrit) in epidemiologically transitioning communities 
that aims to reduce the risk of diabetes and hypertension 
and concomitantly improve the management of either 
conditions by implementing a comprehensive communi-
ty-based innovative intervention programme in the two 
geographically and culturally distinct study sites, Sonipat 
(Haryana, north India) and Visakhapatnam or Vizag 
(Andhra Pradesh, south India). This paper describes the 
design and methods of UDAY- A Comprehensive Diabetes 
and Hypertension Prevention and Management Program 
In India.
MEthods
study design
UDAY has a pre-post evaluation design with representa-
tive cross-sectional surveys before (in year 1 at baseline, 
preintervention) and after the intervention (in year 5). 
The main research question is whether a multicompo-
nent, multilevel, cost-effective, comprehensive interven-
tion programme will improve the prevention, detection 
and optimal management of diabetes and hypertension 
in the two selected study sites. 
We selected a pre-post evaluation design due to the 
following reasons. We wanted to evaluate if multicompo-
nent interventions delivered at multiple levels in a compre-
hensive manner can improve outcomes. Further, we also 
wanted to understand and examine the operational part 
of the programme implementation to gain insights into 
underpinning factors behind success or failure that can 
inform possible replication and scale up in the future. 
The options for an implementation study of this nature 
with process outcomes are either a pre-post design or 
quasi-experimental design or step wedge design. We 
deemed a step wedge to be too complicated for this eval-
uation, and given that quasi-experimental design would 
not have enough power to decipher real differences, we 
chose a pre-post design. This was also aimed at cutting 
down costs.
At baseline, in year 1, five surveys were conducted 
among the general population, among patients, among 
healthcare providers including physicians and phar-
macists and in health facilities to guide intervention 
development and impact assessment. Similar assessment 
is planned after the intervention, in year 5.
The specific objectives these assessments are to
 ► Determine the prevalence, awareness, the knowledge 
levels about diabetes and hypertension, the propor-
tion treated and controlled among a representative 
sample (n=12 000) of adults aged ≥30 years in the 
selected study areas. (Population survey)
 ► Determine the patient knowledge levels and self-man-
agement skills among a convenience sample (n=400) 
of those diagnosed with diabetes and hypertension in 
the selected study areas. (Patient survey)
 ► (a) Determine healthcare providers’ (physicians’) 
knowledge and practices related to diabetes and 
hypertension management among a convenience 
sample (n=50) of healthcare providers’ in the selected 
study areas. (b) Determine pharmacists’ knowledge 
related to diabetes and hypertension and dispensing 
practices among a convenience sample of pharmacists 
(n=350). (Provider survey)
 ► Determine the level of access and potential barriers 
to diabetes and hypertension care provided by the 
public healthcare system in the selected study areas 
(n=50). (Facility survey)
 ► Determine the cost-effectiveness of the intervention 
programme in improving diabetes and hypertension 
treatment and management outcomes in the study 
areas. (Using population survey, Geographical Infor-
mation System (GIS) data and project implementa-
tion data)
study sites
We are undertaking this comprehensive diabetes and 
hypertension prevention and management programme 
in two epidemiologically transitioning areas located 
in Sonipat in Haryana and Vizag in Andhra Pradesh 
(figure 1, online supplementary file 1).
We defined the areas and their subareas using the 
following terminology:
 ► Sites—A bounded geographic area within which we 
have defined distinct rural and urban subsites for the 
study. Each site has been defined such that it contains 
approximately 200 000 people. Sonipat and Vizag are 
each a site.
 ► Subsites—Within each site, we have defined one 
rural and one urban subsite for study. Each subsite is 
geographically bounded and contains a population of 
approximately 100 000. Within Sonipat and Vizag, we 
have defined two subsites each (rural and urban).
 ► Total project—The total project is the summation of 
the two sites, including the four subsites (two subsites 
within each site). Therefore, the total population 
under the study is approximately 400 000.
Intervention programme
We propose to implement a priority set of synergistic inno-
vative ecosystem interventions (figure 2 and table 1), with 
the overarching goal to prevent, detect, reduce the risk 
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of diabetes and hypertension and to improve the treat-
ment and management of individuals with either of the 
conditions in the study sites. We hypothesise (figure 3) 
that education of the public on diabetes, hypertension 
and related risks will lead to increased self-referral and 
prevention, while education of the healthcare providers 
will promote opportunistic screening for diabetes, hyper-
tension and related risks, and purposeful implementa-
tion of evidence-based diagnostic (to screen, stratify by 
risk) and management guidelines (to initiate appropriate 
therapy).
Following the baseline assessments, a comprehensive 
intervention programme is being currently implemented. 
The intervention components include
 ► tailored health promotion using social marketing 
approaches for increasing public awareness and 
promoting population risk factor modification and 
reduction;
 ► community-based screening of all adults aged ≥30 
years for identifying those at high risk of diabetes 
and/or hypertension or with disease to link to the 
healthcare system, leveraging task-sharing approaches 
using technology-enabled health workers;
 ► patient education using technology-enabled health 
workers,
 ► healthcare provider training on evidence-based 
management guidelines;
 ► implementation of a quality improvement programme 
and diabetes registry;
 ► advocacy with governments and other stakeholders to 
improve access to healthcare.
It is expected that the comprehensive interventions will 
increase over baseline the levels of public awareness and 
knowledge about diabetes and hypertension; those aware, 
diagnosed, treated and controlled to recommended targets; 
and the use of guideline-based management by providers. 
Detailed outcome assessment metrics is provided in table 2. 
This is anticipated to improve health outcomes and access 
to healthcare for people living with diabetes and hyper-
tension in India as well as provide a model of healthcare 
which is low-cost, community-based and context-relevant 
in a milieu of rapid rise in these chronic conditions.
Intervention development
We used evidence based interventions and leveraged the 
results from the baseline surveys (population, patient, 
Figure 1 Study sites.
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Figure 2 Priority interventions in UDAY.
Table 1 Innovations in UDAY
Intervention domain Approach Target
Prevention, early detection and referral Culturally tailored health promotion, 
screening
400 000 population
Capacity building, task shifting of healthcare providers CME, short trainings, distance learning, QIP  Healthcare providers
Early diagnosis and prevention of complications Registry 10 000 patients
m-health system Electronic data system+DSS Adult population
Electronic data capture Tablet-based surveys 12 000
Spatial and built environment assessment Geographical Information System mapping All study areas
Improved access to medicines by social marketing 
initiatives
Improving quality of services 300 pharmacists
Culturally tailored patient education and networks for 
enabling self-care
Using health workers Patients
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facility and providers) to develop and refine the inter-
ventions, which were subsequently piloted. For example, 
from population survey we found that there were differ-
ences in the awareness of risk factors for developing 
diabetes/hypertension across rural/urban areas and 
the two study sites in north and south India. Therefore, 
taking this into cognizance, we designed the tailored 
health promotion programme and messages to be deliv-
ered by trained health workers to increase awareness 
about the risk factors. Facility and providers’ surveys 
helped us to design the training programme for training 
healthcare providers as well as to conduct advocacy to 
improve access to the health system. Similarly, findings 
from the patients’ survey helped us to focus the training 
of health workers on building self-management skills of 
people with diabetes/hypertension and for developing 
patient networks.
sample for the population survey
We based our sample size calculation on the prevalence 
of diabetes, which has a lower prevalence than hyperten-
sion, in previously reported studies in India. Anticipating 
a response rate of 85% with a design effect factor of 1.5 (to 
account for cluster sampling) and a confidence level of 
1.96, the sample size estimates were generated for males 
and females in three age strata (30–49, 50–69, 69 and 
above) in each setting (urban, rural). About 2968 subjects 
were estimated to be required per urban subsite (Sonipat 
and Vizag) and 2942 subjects per rural subsite (Sonipat 
and Vizag). The total estimated sample was 11 820, which 
was increased to 12 000 to obtain equal samples in both 
urban and rural areas. Sample weights were generated for 
estimating the prevalence of diabetes, hypertension and 
related cardiometabolic (CMD) risk factors at the district 
level.
survey sampling and participant selection
Population survey
Two representative population-based cross-sectional 
surveys with independent samples and identical method-
ologies at baseline and at the end of intervention will be 
conducted, which will provide estimates of the burden 
and changes in the prevalence of diabetes, hyperten-
sion and related CMD risk factors. In addition, those 
recruited for the first survey at baseline (which has been 
completed) will be followed up as a cohort to estimate the 
incidence of new CMD risk factors, disease, healthcare 
utilisation, diabetes and hypertension-related morbidity 
and mortality.
The first population survey (baseline survey) was done 
among a representative sample of adults aged ≥30 years 
residing in the selected study areas of Sonipat and Vizag. 
Inclusion criteria were (a) adults aged ≥30 years residing 
in the sampled urban and rural areas of Sonipat and 
Vizag, respectively; and (b) willing to participate and 
provide informed consent.
We excluded individuals who were unwilling to provide 
informed consent and those with serious chronic illnesses 
[such as that of the liver (cirrhosis), kidneys (renal 
failure) or malignancies], and pregnant women.
For the baseline survey, a multistage random sampling 
technique was deployed to obtain a representative sample 
of adults aged ≥30 years, using data from the most recent 
census of 2011. In addition, a manual enumeration and 
mapping of all households and structures was conducted in 
all the study areas (all census enumeration blocks (CEBs) in 
urban areas and villages in rural) to identify households and 
structures constructed since the last census (table 3). CEBs 
are considered as the primary sampling unit in urban areas 
and villages in the rural areas, respectively. On average, 
about 100–125 households with a population of 650–700 
persons would generally constitute a CEB. This enabled a 
complete sampling frame for the selection of households 
for the survey and thus provided an equal chance of selec-
tion to each household. Besides, it also helped identify 
potential recipients of the intervention programme (ie, 
adults aged ≥30 years) in the study sites.
In each subsite, 85 clusters were randomly selected 
(urban Sonipat: 85/200 CEBs; urban Vizag: 85/207 CEBs; 
and rural Sonipat: 85/168 clusters; rural Vizag: 85/147 
clusters) according to probability proportional to size 
(figure 4). In rural subsites, bigger villages were divided 
into clusters with 75–300 households. From each cluster 
in the urban and rural subsites, 18–25 households were 
randomly selected and one eligible male and female were 
selected randomly within each household using Kish table. 
In Sonipat district, 3675 households participated in base-
line survey (rural: 1881; urban: 1794) with total being 6208 
participants (rural: 3104; urban: 3104). In Vizag district, 
3589 households (rural: 1817; urban: 1772) participated in 
the baseline survey with total being 6035 participants (rural: 
3069; urban: 2966). Thus, we had 12 000 individuals from 
both urban and rural areas of north and south India.
Figure 3 Intervention framework.
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Table 2 Assessment of intervention outcomes
Indicator Target population Metric Evaluation methodology
1. Patient 
outcomes
Diabetes and 
hypertension 
patients
% implementing lifestyle change (meet the 
recommended levels of physical activity and intend to 
and/or implement dietary changes)
Baseline and endline surveys, 
diabetes registry
% engaging in self-monitoring/testing Baseline and endline surveys, 
diabetes registry
% increase in correct self-management practices Baseline and endline surveys, 
diabetes registry
% increase in knowledge on diabetes and 
hypertension
Baseline and endline surveys, 
diabetes registry
% of patients on treatment, whose diabetes, 
hypertension is successfully controlled, that is, 
HbA1C≤7 %/blood pressure ≤130/80 mm Hg
Baseline and endline surveys, 
diabetes registry
2. Awareness and 
knowledge about 
diabetes and 
hypertension
General 
population
% increase in knowledge of diabetes, hypertension 
and their risk factors
Baseline and endline surveys
% increase in detection rate and in seeking healthcare Baseline and endline surveys, 
screening programme
% implementing lifestyle change (meet the 
recommended levels of physical activity and intend to 
and/or implement dietary changes)
Baseline and endline surveys, 
screening programme
% exposed to health promotion campaign Baseline and endline surveys, 
screening programme
3. Provider 
knowledge and 
practices
Physicians, other 
health workers
Numbers who participate in training programmes Training participation data
% increase in knowledge related to diabetes and 
hypertension management
Baseline and endline surveys 
of providers, diabetes registry
% increase in practices related to diabetes and 
hypertension management and providing lifestyle 
advice
Baseline and endline surveys 
of providers, diabetes registry
Pharmacists % of pharmacists who identify people at risk of and 
with diabetes, hypertension
Baseline and endline surveys 
of providers
% increase in pharmacists dispensing and filling 
prescriptions correctly
Baseline and endline surveys 
of providers, diabetes registry
4. Programme 
cost-effectiveness
Patients with 
diabetes
Cost per diabetic patient treated to recommended 
target
Baseline and endline surveys 
of patients, programme cost 
data, diabetes registry
% reduction in out-of-pocket expenditure Baseline and endline surveys 
of patients, diabetes registry
General 
population
Cost per diabetes case identified Surveys, screening 
programme, programme cost 
data
5. Access to 
treatment
Healthcare system Improvements in access to and availability of 
medications
Baseline and endline surveys 
of patients, facility survey, 
diabetes registry
% increase in the proportion patients who report that 
medicines are easily available
Baseline and endline surveys 
of patients, facility survey, 
diabetes registry
% reduction in stock outs of medicines Baseline and endline surveys 
of patients, facility survey, 
diabetes registry
Adherence to Indian Public Health Standards 
guidelines on drugs, services
Facility survey, diabetes 
registry
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data collection for the population survey
For the baseline survey, trained health workers visited the 
selected participants at their homes. Written informed 
consent was sought and obtained from the selected indi-
viduals prior to data collection and a unique identifica-
tion number was assigned. For each participant, data 
collection comprised an interviewer-administered ques-
tionnaire, a brief physical examination (height, weight, 
waist circumference, hip circumference, blood pressure, 
body fat percentage), blood and urine collection as 
detailed below.
Information on demographics, socioeconomic char-
acteristics, behavioural risk factors (tobacco use, alcohol 
use, diet and physical inactivity), family history of various 
NCDs, female reproductive history, general awareness 
about diabetes and hypertension, risk factors, prevention, 
Table 3 Manual enumeration of study areas
Study site Structures Households Population≥30 years
Total population
(census 2011)
Sonipat urban subsite 24 408 20 406 41 981 102 292
Sonipat rural subsite 28 813 17 283 40 850 100 935
Vizag urban subsite 16 888 39 504 70 735 153 721
Vizag rural subsite 33 799 30 817 59 540 121 209
Figure 4 Sample selection for the baseline survey.
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symptoms and diagnosis, complications, treatment and 
management, medical history of NCDs (diabetes, hyperten-
sion, coronary artery disease, myocardial infraction, stroke, 
heart failure, chronic kidney disease, peripheral vascular 
disease, chronic obstructive pulmonary disease, asthma), 
quality of life, mental health, social support, cost of health-
care and healthcare utilisation was collected using a tablet-
based application (table 4).
Body measurements such as height, weight, waist and hip 
circumferences, blood pressure and body fat measurement 
by bio impedance using TANITA were also obtained using 
standardised equipment.
Bio-samples (fasting blood and morning urine) were 
collected for the laboratory estimation of fasting plasma 
glucose, glycated haemoglobin (HbA1c), lipids, serum 
creatinine, urea, urine microalbumin and urine creatinine. 
We have also stored the biosamples for future analysis of 
emerging biomarkers and genetics.
data collection for the patient survey
Trained research staff visited health facilities located 
in the aforementioned selected study areas and 
approached patients attending outpatient section of 
the health facilities and identified those with the diag-
nosis of diabetes and/or hypertension based on their 
prescription note for participating in the study. Written 
informed consent was sought and obtained from the 
individuals prior to data collection, and data collection 
comprised an interviewer-administered questionnaire 
(table 5).
The patient survey was done among a convenience 
sample of 400 patients having diabetes and/or hyper-
tension attending health facilities and residing in the 
selected study areas of Sonipat and Vizag.
Inclusion criteria: We included patients with diabetes and 
or hypertension residing/attending health facilities in 
the sampled urban and rural areas of Sonipat and Vizag, 
respectively, and were willing to participate and provide 
informed consent.
Exclusion criteria: We excluded those unwilling to 
provide informed consent.
data collection for the provider surveys
Trained research staff visited health facilities located in 
the aforementioned selected study areas and approached 
healthcare providers (physicians and pharmacists). 
Written informed consent was sought and obtained from 
the individuals prior to data collection, and data collec-
tion comprised an interviewer-administered question-
naire (table 6).
The physician survey was done among a convenience 
sample of 50 physicians working in the health facilities 
located in the selected study areas of Sonipat and Vizag.
Inclusion criteria: We included physicians working in 
health facilities located in the sampled urban and rural 
areas of Sonipat and Vizag, respectively, and were willing 
to participate and provide informed consent.
Exclusion criteria: Those unwilling to provide informed 
consent were excluded.
The pharmacist survey was conducted among 350 phar-
macists by trained research staff in the aforementioned 
selected study areas. Written informed consent was 
sought and obtained from the individuals prior to data 
collection, and data collection comprised an interview-
er-administered questionnaire.
Inclusion criteria: We included pharmacists who were 
located in the sampled urban and rural areas of Sonipat 
and Vizag, respectively, dispensing medicines for diabetes 
and hypertension, were willing to participate and provide 
informed consent.
Exclusion criteria: Those not dispensing medicines for 
diabetes and hypertension and unwilling to provide 
informed consent were excluded.
data collection for the health facility survey
Permission was sought and obtained from respective 
district medical/health officers prior to data collection, 
and data collection comprised an interviewer-admin-
istered questionnaire (table 7). Trained research staff 
visited public healthcare facilities located in the afore-
mentioned selected study areas and approached the 
person/medical officer in charge.
The facility survey was done in 50 public healthcare 
facilities (subcentres, primary and community health 
centres, taluk/district/tertiary hospitals) situated in the 
selected study areas of Sonipat and Vizag.
biosample collection and storage
Blood samples (in fasting state) were collected in plain, 
fluoride and EDTA vacutainers (Becton & Dickinson, 
USA) by trained phlebotomists in households or in camps 
arranged close to the households. Samples for estimation 
for blood glucose were kept in ice and transferred to labo-
ratories within 2 hours of sample collection and immedi-
ately centrifuged. Samples were centrifuged at 2500 rpm 
for 15 min and serum/plasma were transferred into the 
cryo-vials which were stored in −20°C immediately. Buffy 
coat from EDTA vacutainers were separated and stored 
into cryo-vials for DNA extraction. Red blood cells were 
washed thrice with normal saline and were stored for 
analysis of fatty acids in future. First early morning voided 
urine was collected from the participants and has been 
stored in deep freezer for future analysis of metabolites. 
All these samples were transported to the biochemistry 
laboratory at the Public Health Foundation of India 
(PHFI) in dry ice on the day of collection from Sonipat 
and Vizag, where they were stored at −80°C.
All clinical chemistry parameters were analysed on 
autoanalyzer Cobas 311 using reagents from Roche 
Diagnostics, Switzerland. Glucose was estimated using 
Hexokinase method, cholesterol by enzymatic choles-
terol oxidase method, triglycerides by GPO-PAP method 
and high-density lipoprotein and low-density lipoprotein 
by direct method, aspartate aminotransferase and alanine 
transaminase were estimated according to International 
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Federation of Clinical Chemistry (IFCC) method without 
pyridoxal phosphate, bilirubin total by Diazonium ion 
method, bilirubin direct by Diazo with sulphanilic acid 
method, urea by kinetic method, creatinine by Jaffe’s 
method and urinary microalbumin using immuno turbi-
dimetric method. HbA1c was assayed by high-perfor-
mance liquid chromatography method using reagents 
from Bio-Rad Laboratories, Hercules, California, USA.
Two levels of internal controls were run with every 
batch of samples. The intra-assay and inter-assay coeffi-
cient of variation for all the parameters were <3% and 
<5%, respectively.
The biochemistry laboratory is part of External Quality 
Assurance program from RIQAS for clinical chemistry 
parameters and HbA1c assay.
Evaluation of cost-effectiveness
This will be evaluated by assessing the costs and bene-
fits of the multicomponent, multilevel comprehensive 
interventions in improving diabetes-related health 
outcomes. Data on healthcare utilisation and costs, 
as well as that of out-of-pocket expenditure will be 
collected in the baseline and endline surveys. In addi-
tion, data on direct costs including the cost of personnel, 
provider training, medications, lab tests and supplies, 
screening, outpatient visits and costs related to the social 
marketing campaign will be obtained during the imple-
mentation process. The total costs entailed to identify 
a person with diabetes as well as to appropriately treat 
that person to recommended targets based on guidelines 
will be measured. In addition, we will model the costs 
accrued from the use of drugs and other related inter-
ventions, based on results of other such comprehensive 
programmes and do a comparison to assess effective-
ness. Based on the aforesaid indicators, we will develop 
a comprehensive cost-effectiveness model to assess the 
overall programme effectiveness.
Table 5 Summary of indicators, measures, methods and instruments for the patient survey
Indicators Measures Methods Instruments
Demographics and 
socioeconomic 
characteristics
Age, sex, education, income, occupation, contact 
details
Questionnaires CARRS, Sentinel Surveillance 
Study
Behavioural risk factors Tobacco use
Alcohol use
Questionnaire CARRS, Sentinel Surveillance 
Study
Awareness and knowledge of 
diabetes and hypertension
Awareness of risk factors, symptoms and diagnosis, 
cut-off levels for diagnosis, complications, 
treatment and management
Questionnaire Developed for UDAY
Diabetes and hypertension 
related medical history
Diagnosis, healthcare utilisation, control, 
self-management practices, complications, 
comorbidities and treatment adherence
Questionnaire Developed for UDAY
Health-related quality of life Mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression (related to CMDs and risk 
factors)
Questionnaire European Quality of Life 5 
Dimensions questionnaire
Mental health Depression Questionnaire Modified from Patient Health 
Questionnaire 9 
Social well-being Social support Questionnaire Developed for UDAY
Healthcare utilisation Hospital visits in the past 12 months and healthcare 
expenditure
Questionnaire CARRS
CARRS, Centre for  cArdiometabolic Risk Reduction in South Asia; CMDs, cardiometabolic diseases.
Table 6 Summary of indicators, measures, methods and instruments for the provider survey (physicians)
Indicators Measures Methods Instruments
Socio-demographic details Age, gender, qualification, years of practice, 
patient load, training in diabetes and hypertension 
management
Questionnaire Developed for 
UDAY
Knowledge and practice pertaining to 
diabetes and hypertension diagnosis 
and evaluation of complications
Signs and symptoms, diagnosis and cut-off levels for 
diagnosis, evaluation for complications
Questionnaire Developed for 
UDAY
Treatment practices for diabetes and 
hypertension
Lifestyle modifications, prevention and management 
of complications, names of medicines prescribed 
commonly
Questionnaire Developed for 
UDAY
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GIs-based mapping of study households and neighbourhood-
built environment
All households as well as the study areas, including various 
points of interest as indicated below, were geocoded using 
GIS mapping. This will be used to comprehensively assess 
the built environment (BE) and its impact on diabetes 
hypertension and risk factors. GIS-based techniques will 
be employed to study the association between BE features 
and diabetes, hypertension and related risk factors.
Specially trained field staff visited all participant house-
holds and used handheld Garmin Global Positioning 
System (GPS) receivers to capture GPS locations of the 
households. The captured GPS coordinates were verified 
using Google Earth to see if the locations matched the 
actual locations.
Table 8 shows the BE features from the study areas that 
were located and mapped.
Household GPS locations and neighbourhood BE 
features were integrated with participant data collected 
as part of the baseline data collection. An overview of the 
GIS mapping is provided in figure 5. Area boundaries 
were obtained from government records and digitised. 
All spatial data were integrated into a spatial database, 
and ArcGIS software was used to carry out the following 
spatial analysis methods.
 ► Distance calculations: Distance between participant 
households and features of interest such as health-
care facilities, food and alcohol outlets, and parks, 
and their association between CMD and risk factors.
 ► Spatial aggregation: Aggregation of features such as 
number of food outlets and parks in the neighbour-
hood and relationship with CMD and risk factors.
 ► Clustering: Identify clustering of CMD and risk factors 
(hotspots) and determine if disease clusters are of 
sufficient geographic size and concentration to have 
not occurred by chance.
 ► Spatial smoothing and interpolation: Used to derive 
a spatial surface from sampled data points (filling in 
where data are unobserved) or to smooth across poly-
gons (aggregate data) to create more robust estimates.
 ► Spatial regression: Use of spatial regression methods 
such as geographically weighted regression to further 
understand the relationship between BE and CMD 
risk factors as standard statistical regression models, 
which assume independence of the observations, are 
not appropriate for analysing spatially dependent 
data.
Data management
Data were collected in electronic format using custom-
ised android-based software on a tablet platform and 
Table 7 Summary of indicators, measures, methods and instruments for the health facility survey
Indicators Measures Methods Instruments
Coverage statistics Types of services offered, number of hours and days services provided 
per week, population covered, average daily outpatient department 
attendance, number of beds available, status of National Program for 
Control and Prevention of Diabetes, Cardiovascular Disease and Stroke 
implementation
Questionnaire Adapted from SARA 
tool of WHO
Recommended 
manpower list
Numbers working at district hospitals, community health centres, primary 
health centres and subcentres against recommended numbers and reasons 
for lack of recommended personal
Additional manpower required for NCDs
Checklist, 
questionnaire
Adapted from IPHS 
and SARA
Recommended 
medication list
Availability of medicines at district hospitals, community health centres, 
primary health centres and subcentres against recommended medicines 
and reasons for lack for recommended medicines
Additional medicines required for NCDs
Checklist, 
questionnaire
Adapted from IPHS 
and SARA
Recommended 
equipment list
Numbers of equipment available at district hospitals, community health 
centres, primary health centres and subcentres against recommended 
equipment and their functional status
Additional equipment required for NCDs
Checklist, 
questionnaire
Adapted from IPHS 
and SARA
Recommended 
investigative services 
list
Investigative services available at district hospitals, community health 
centres, primary health centres and subcentres against recommended 
services and reasons for their unavailability
Additional investigative services required for NCDs
Checklist, 
questionnaire
Adapted from IPHS 
and SARA
Recommended 
activities list
Frequency of recommended activities conducted and methods of 
conducting at district hospitals, community health centres, primary 
health centres and subcentres for current diagnosis, treatment and health 
promotion
Reasons for not conducting the activities
Checklist, 
questionnaire
Adapted from IPHS 
and SARA
Availability of national 
guidelines and training 
of healthcare providers
Availability of national guidelines for diagnosis and management of 
diabetes, hypertension and CVD and training of healthcare providers in the 
facility to diagnose and manage diabetes, hypertension and CVD
Questionnaire Adapted from IPHS 
and SARA
CVD, cardiovascular disease; IPHS, Indian Public Health Standards; NCD, non-communicable  diseases ; SARA, Service Availability and 
Readiness Assessment.
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uploaded to server on a real-time basis (figure 6). For 
ensuring quality control, all validation, range and logical 
checks were in-built in the software. Error reports were 
generated biweekly and sent to the study sites for recti-
fication. Errors were checked against completion of the 
questionnaire, identifiers and adherence to the sampling 
strategy of interviews (only one man and one woman 
from single household).
Further, site research teams identified any other issues 
and reported to centralised team for the corrections. Data 
correction took place concomitantly with the conduct 
of the baseline survey. Similarly, biosample reports were 
matched with participant questionnaires and the final 
data were locked after all matching and rectification of 
errors.
Analysis plan
Data were entered into a database designed specifically for 
the project, housed at PHFI and accessible only to inves-
tigators and designated study staff. Data will be analysed 
using Stata/SE V.12.1 for Windows software. Descriptive 
statistics will be done, and the data expressed as frequen-
cies and percentages for categorical variables and means 
and SD for normally distributed continuous variables or 
IQRs otherwise. Differences between gender groups, age 
groups, socioeconomic groups, study sites, time periods 
and individual hypotheses will be tested using appropriate 
analytical statistical tests (χ2 tests for categorical variables, 
t-tests continuous variables, multiple linear regression for 
continuous variables and multiple logistic regression for 
categorical variables). Stratified analysis will be done to 
assess for potential confounding and effect modification 
by other variables. A P value of <0.05 will be considered to 
Table 8 Characteristics of the built environment in study sites
Environment features Points of interest N Sonipat Vizag
Healthcare facilities Government health facilities 64 36 28 
Private hospitals and clinics 228 147 81 
Registered medical practitioners and unqualified practitioners 220 195 25 
Other health professionals 118 115 3 
Pharmacies 337 224 113 
Medical laboratories 46 30 16 
Food outlets Hotels 165 4 161 
Restaurants 33 10 23 
Small eateries 97 40 57 
Provision/department stores 313 196 117 
Fruit/vegetable/juice outlets 254 36 218 
Meat/fish shops 128 24 104 
Public distribution system (ration) shops 52 344 52 
Milk outlets 128 6 122 
Bakeries/sweet shops 123 73 50 
Tobacco outlets Pan shop 713 17 696
Alcohol outlets Authorised government outlets 45 31 14
Unauthorised alcohol outlets 100 100 
Recreational facilities Parks 91 62 29 
Walking tracks 6  6 
Play grounds 50 43 7 
Fitness / yoga centres 10 6 4 
Other Anganwadis, schools, temples, and so on 633 124 509
Figure 5 GIS mapping overview.
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indicate statistical significance. Multilevel modelling will 
be undertaken by clusters and households as potential 
levels.
dIsCussIon
UDAY is one of the largest community-based intervention 
studies established in India to implement and evaluate a 
multicomponent, multilevel, cost-effective, comprehen-
sive intervention programme to concomitantly improve 
the prevention, detection and optimal management of 
diabetes and hypertension, which together constitute the 
leading NCDs in India. Their high and rising burden, 
coupled with huge healthcare costs, underlines the need 
for cost-effective community-based approaches supple-
mented by measures to strengthen the health system to 
address both these NCDs effectively as envisaged in UDAY.
Most of the evidence on community interventions for 
chronic NCDs are from developed countries.5 6 In the last 
two decades, some evidence has emerged from low-in-
come, middle-income countries as well but not quite 
commensurate to the disproportionate burden borne 
by them (80% NCD mortality).7 8 This is due to several 
reasons including resources to conduct such large proj-
ects as well as the technical capacity.7 8 However, avail-
able information indicates that results are likely better 
in low-income, middle-income  countries (eg, Isfahan 
Healthy Heart Program in Iran, diabetes prevention 
programmes in China and India).7–9 We have taken into 
account findings of such prior research and attempted to 
address the reported gaps by adding relevant elements to 
the design of our study. For instance, most such interven-
tion programmes have entailed community-based inter-
ventions (largely targeting lifestyle modification) but have 
not had active healthcare system and advocacy interven-
tions as proposed in our study. In addition, many of the 
diabetes prevention programmes have targeted high-risk 
groups and not the general free-living population as envis-
aged in this programme. Further, we have used several 
innovations (see table 1) including task shifting/sharing 
of care to non-physician health workers by the extensively 
leveraging low-cost m-health technology to enable and 
empower them to screen and deliver interventions as 
well as physicians to treat patients as per evidence-based 
algorithms. We have also used GIS mapping to charac-
terise the sites, BE, healthcare facilities and providers 
to examine the influence of BE on diabetes/hyperten-
sion and their risks factors as well as care pathways that 
patients undertake in order to deliver interventions in a 
more focused way. In addition, we have built-in extensive 
stakeholder and community engagement in the study 
implementation which should aid in improving accept-
ability and buy-in for the intervention programme.
Further, the community-based cohorts established will 
not only facilitate tracking of the trends in risk factors 
and diseases in rapidly transitioning populations in India, 
but also serve as well-characterised population platforms 
Figure 6 Data collection and management pathway.
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for embedding and evaluating new research questions of 
public health relevance in combating the rise of NCDs.
Notably, a unique strength of UDAY besides occurring in 
a low-income, middle-income country setting where there 
are limited community-based projects compared with 
various other community-based projects conducted in 
both developed countries and low-income, middle-in-
come countries, which have either addressed preven-
tion or management of select chronic conditions, is that 
UDAY aims to address both prevention and management 
of concurrently and comprehensively.
However, the study has some limitations. First, we used 
a pre-post study design for evaluating the effect of our 
interventions. Though a randomised controlled trial is 
a better design to evaluate the effectiveness of interven-
tions, providing a higher level of evidence than a pre-post 
design, to study the effect of multicomponent interven-
tions delivered at multiple levels in a comprehensive 
manner in a large population over a vast geographic area, 
we considered the pre-post design as more appropriate 
for our study. Further, we also wanted to understand and 
examine the operational part of the programme imple-
mentation to gain insights into underpinning factors 
behind success or failure that can inform possible replica-
tion and scale up in the future.
Second, our study does not include controls for the 
comparison. Given the size of the population covered by 
the interventions, we would have had to recruit control 
communities of similar size and numbers, which was not 
feasible from an implementation and resources avail-
ability point of view. However, our baseline and endline 
surveys that evaluate the impact are done on indepen-
dent random samples of the population, which should 
provide robust data regarding potential changes over 
baseline in the levels of public awareness and knowledge 
about diabetes and hypertension; those aware, diagnosed, 
treated and controlled to recommended targets; and the 
use of guideline-based management by providers leading 
to improved health outcomes and access to healthcare for 
people living with diabetes and hypertension in India. In 
addition, we will be comparing our results with ongoing 
national survey data on NCDs and their risk factors 
(National Family Health Survey, Annual Health Survey, 
District Level Household Survey) as well as a New National 
NCD survey which is being implemented currently. This 
will help assess secular trends and evaluate our findings 
in conjunction with such trends if any. Also we did not 
account for the regression to the mean as there would be 
at least some people both in the endline and baseline. We 
will do sensitivity analysis to explore this bias.
Third, one of the major interventions of our programme 
is to implement a community-based screening, follow-up 
and educational programme through health workers. 
We specifically hired and trained health workers to 
implement this interventional component, which might 
add to the cost of implementing a community-based 
diabetes and hypertension prevention and management 
programme. However, the additional cost is likely to be 
minimal as indicated by previous modelling estimates of 
training and using health workers.
Fourth, we are using multicomponent interventions 
at multiple levels (health promotion campaigns, health 
workers-led home-based screening, follow-up and educa-
tion, training of healthcare providers, registry for facili-
ty-based improvement in quality of care, patient networks 
and advocacy to strengthen the health system) which 
makes it difficult to evaluate the individual contribution 
of each intervention. However, the purpose is to deliver it 
in a comprehensive manner to improve outcomes, which 
to our knowledge has hitherto not been implemented in 
similar settings, and not to tease out impact of individual 
interventions in a milieu where many individuals have 
elevations of multiple NCD risk factors and suffer often 
from comorbid conditions that require to be addressed 
comprehensively.
It is anticipated that the results obtained from the study 
will inform policymakers on the most appropriate commu-
nity and health system-based approaches that are effective 
in stemming the rising burden of diabetes and hyperten-
sion in India and countries with similar challenges.
Acknowledgements The UDAY project is led by the Public Health Foundation of 
India, Gurgaon, India in collaboration with Population Services International, India 
and Project HOPE. We acknowledge the contributions of the field and research staff 
of the project. The funder has no role in the design, implementation, and evaluation 
of the project as well as in the writing of this paper. All contents of this paper are 
solely the responsibility of the authors.
Contributors SM, KSR, DP and NT conceived the study. SM wrote the first draft 
of the manuscript. PJ, SG, NSV, RR, CM, RG, BR and SK wrote specific sections 
of the manuscript as well as contributed to the design and implementation of 
the study. BR and SK also coordinate the activities in the study sites and provide 
technical support. SM, SG, PJ and NSV contributed to the collection and assembly 
of data. All authors provided input into the study design, as well as provided critical 
intellectual input for revision of the manuscript and approved the final version of the 
manuscript.
Funding It is supported by an unrestricted educational grant from Eli Lilly and 
Company under the Lilly NCD Partnership Program. 
disclaimer The funding agency had no role in the design, conduct or analysis of 
the study, and no role in the decision to submit the protocol for publication. 
Competing interests None declared.
Ethics approval Institutional Ethics Committee (IEC) of the Public Health 
Foundation of India.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. World Health Organization (WHO) Country Office for India. 
National multisectoral action plan for prevention and control 
of noncommunicable diseases. India, New Delhi: World Health 
Organization (WHO) Country Office for India, 2013.
 2. International Diabetes Federation. IDF Diabetes Atlas. 7th edn. 
Brussels, Belgium: International Diabetes Federation, 2015.
15Mohan S, et al. BMJ Open 2018;8:e015919. doi:10.1136/bmjopen-2017-015919
Open access
 3. Srinath Reddy K, Shah B, Varghese C, et al. Responding to the threat 
of chronic diseases in India. Lancet 2005;366:1744–9.
 4. Mohan S, Koller T. Hypertension and related comorbidities in India: 
Implications for the health system.  India, New Delhi: World Health 
Organization (WHO) Country Office for India, 2013.
 5. Berra K, Franklin B, Jennings C. Community-Based Healthy Living 
Interventions. Prog Cardiovasc Dis 2017;59:430–9.
 6. Puska P. Why did north karelia-finland work? Is it transferrable? Glob 
Heart 2016;11:387–91.
 7. Sarrafzadegan N, Kelishadi R, Esmaillzadeh A, et al. Do lifestyle 
interventions work in developing countries? Findings from the isfahan 
healthy heart program in the islamic republic of Iran. Bull World 
Health Organ 2009;87:39–50.
 8. Harati H, Hadaegh F, Momenan AA, et al. Reduction in incidence 
of type 2 diabetes by lifestyle intervention in a middle eastern 
community. Am J Prev Med 2010;38:628–36.
 9. Rawal LB, Tapp RJ, Williams ED, et al. Prevention of type 2 diabetes 
and its complications in developing countries: a review. Int J Behav 
Med 2012;19:121–33.
 10. Nair M, Ali MK, Ajay VS, et al. CARRS Surveillance study: design and 
methods to assess burdens from multiple perspectives. BMC Public 
Health 2012;12:701.
 11. Reddy KS, Prabhakaran D, Chaturvedi V, et al. Methods for 
establishing a surveillance system for cardiovascular diseases 
in Indian industrial populations. Bull World Health Organ 
2006;84:461–9.
 12. International Institute for Population Sciences (IIPS) and Macro 
International. National Family Health Survey (NFHS-3), 2005–2006. 
Volume II. India, Mumbai: IIPS, 2007.
 13. World Health Organization. Global Physical Activity Questionnaire 
(GPAQ) analysis guide: World Health Organization. http://www. who. 
int/ chp/ steps/ resources/ GPAQ_ Analysis_ Guide. pdf (assessed 15 
Dec 2015).
 14. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 
countries (the INTERHEART study): case-control study. Lancet 
2004;364:937–52.
 15. EuroQol Group. EuroQol-a new facility for the measurement of 
health-related quality of life. Health Policy 1990;16:199–208.
 16. Poongothai S, Pradeepa R, Ganesan A, et al. Reliability and validity 
of a modified PHQ-9 item inventory (PHQ-12) as a screening 
instrument for assessing depression in Asian Indians (CURES-65). J 
Assoc Physicians India 2009;57:147–52.
